...A. We've delivered a rich pipeline with numerous multi-billion dollar opportunities across diverse indications by the end of 2025. B. And we've established a robust financial position where we have growing revenues, strong balance sheets with $2.7 billion of cash, and approaching profitability. C. Obviously, the highly positive results from the landmark HELIOS-B Phase 3 study and the submission of global regulatory filings for vutrisiran in ATTR cardiomyopathy. D. We also advanced continued innovation for ATTR patients with Phase One data, with nucresiran, really building durable, long-term growth for our TTR franchise. E. We continue to advance mivelsiran, including initial multi-dose results in patients with early onset Alzheimer's disease, and the initiation of the cAPPricorn-1 Phase 2 study in cerebral amyloid angiopathy. F. And we expanded our clinical pipeline with four proprietary CTAs, as well as a number of additional CTAs filed by our partners. G. And we demonstrated exemplary...
